| Krishna G, Goel S, Krishna K A. Alternative Animal Toxicity Testing and Biomarkers [M]//Biomarkers in Toxicology. Amsterdam: Elsevier, 2014: 129-147 |
| Prior H, Casey W, Kimber I, et al. Reflections on the progress towards non-animal methods for acute toxicity testing of chemicals [J]. Regulatory Toxicology and Pharmacology, 2019, 102: 30-33 |
| Organization for Economic Co-operation and Development (OECD). Report on considerations from case studies on integrated approaches for testing and assessment (IATA) [R]. Paris: Environment, Health and Safety Division, Environment Directorate, OECD, 2021 |
| Parish S T, Aschner M, Casey W, et al. An evaluation framework for new approach methodologies (NAMs) for human health safety assessment [J]. Regulatory Toxicology and Pharmacology, 2020, 112: 104592 |
| Richard A M, Judson R S, Houck K A, et al. ToxCast chemical landscape: Paving the road to 21st Century toxicology [J]. Chemical Research in Toxicology, 2016, 29(8): 1225-1251 |
| Hsieh N H, Chen Z W, Rusyn I, et al. Risk characterization and probabilistic concentration-response modeling of complex environmental mixtures using new approach methodologies (NAMs) data from organotypic in vitro human stem cell assays [J]. Environmental Health Perspectives, 2021, 129(1): 17004 |
| World Health Organization. Principles and methods for the risk assessment of chemicals in food [R]. Geneva, Switzerland: World Health Organization, 2012 |
| Bessems J G, Loizou G, Krishnan K, et al. PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: Recommendations from a joint EPAA-EURL ECVAM ADME workshop [J]. Regulatory Toxicology and Pharmacology, 2014, 68(1): 119-139 |
| National Research Council (NRC). Toxicity testing in the 21st Century: A vision and a strategy [R]. Washington DC: Committee on Toxicity Testing and Assessment of Environmental Agents, National Research Council, 2007 |
| Pletz J, Blakeman S, Paini A, et al. Physiologically based kinetic (PBK) modelling and human biomonitoring data for mixture risk assessment [J]. Environment International, 2020, 143: 105978 |
| 管娜, 朱斌, 赵申升, 等. 生理动力学模型及其在健康风险评估中的应用进展和展望[J]. 生态毒理学报, 2024, 19(4): 1-12 Guan N, Zhu B, Zhao S S, et al. The development and future prospective of physiologically based kinetic models and its applications in risk assessment [J]. Asian Journal of Ecotoxicology, 2024, 19(4): 1-12 (in Chinese) |
| Bell S M, Chang X Q, Wambaugh J F, et al. In vitro to in vivo extrapolation for high throughput prioritization and decision making [J]. Toxicology in vitro, 2018, 47: 213-227 |
| Chang X Q, Tan Y M, Allen D G, et al. IVIVE: Facilitating the use of in vitro toxicity data in risk assessment and decision making [J]. Toxics, 2022, 10(5): 232 |
| 王广基, 刘晓东, 柳晓泉. 药物代谢动力学[M]. 北京: 化学工业出版社, 2005: 235 |
| East A, Dawson D E, Brady S, et al. A scoping assessment of implemented toxicokinetic models of per- and polyfluoro-alkyl substances, with a focus on one-compartment models [J]. Toxics, 2023, 11(2): 163 |
| Galetin A. Rationalizing Underprediction of Drug Clearance from Enzyme and Transporter Kinetic Data: From in vitro Tools to Mechanistic Modeling [M]// Nagar S, Argikar U A, Tweedie D J. Enzyme Kinetics in Drug Metabolism: Fundamentals and Applications. Totowa, NJ: Humana Press, 2014: 255-288 |
| Yoon M, Clewell H J 3rd. Addressing early life sensitivity using physiologically based pharmacokinetic modeling and in vitro to in vivo extrapolation [J]. Toxicological Research, 2016, 32(1): 15-20 |
| Kuepfer L, Niederalt C, Wendl T, et al. Applied concepts in PBPK modeling: How to build a PBPK/PD model [J]. CPT: Pharmacometrics & Systems Pharmacology, 2016, 5(10): 516-531 |
| Organization for Economic Co-operation and Development (OECD). Guidance document on the characterisation, validation and reporting of physiologically based kinetic (PBK) models for regulatory purposes [R]. Paris: Environment, Health and Safety Division, Environment Directorate, OECD, 2021 |
| Yoon H, Kim T H, Lee B C, et al. Comparison of the exposure assessment of di(2-ethylhexyl) phthalate between the PBPK model-based reverse dosimetry and scenario-based analysis: A Korean general population study [J]. Chemosphere, 2022, 294: 133549 |
| Kolli A R, Kuczaj A K, Martin F, et al. Bridging inhaled aerosol dosimetry to physiologically based pharmacokinetic modeling for toxicological assessment: Nicotine delivery systems and beyond [J]. Critical Reviews in Toxicology, 2019, 49(9): 725-741 |
| Tebby C, Caudeville J, Fernandez Y, et al. Mapping blood lead levels in French children due to environmental contamination using a modeling approach [J]. The Science of the Total Environment, 2022, 808: 152149 |
| Wetmore B A. Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment [J]. Toxicology, 2015, 332: 94-101 |
| Silva M H. Use of Computational Toxicology Tools to Predict in vivo Endpoints [M]// Gupta R C. Reproductive and Developmental Toxicology (Third Edition). Amsterdam: Elsevier, 2022: 127-146 |
| Linakis M W, Sayre R R, Pearce R G, et al. Development and evaluation of a high throughput inhalation model for organic chemicals [J]. Journal of Exposure Science & Environmental Epidemiology, 2020, 30(5): 866-877 |
| 张浩然, 杨道远, 欧瞳, 等. 化学物危害特征描述中不确定系数制定的研究进展及其应用[J]. 生态毒理学报, 2024, 19(2): 1-11 Zhang H R, Yang D Y, Ou T, et al. Research advances and practical applications of uncertainty factors using in chemical hazard characterization [J]. Asian Journal of Ecotoxicology, 2024, 19(2): 1-11 (in Chinese) |
| Schroeder K, Bremm K D, Alépée N, et al. Report from the EPAA workshop: in vitro ADME in safety testing used by EPAA industry sectors [J]. Toxicology in vitro, 2011, 25(3): 589-604 |
| Sager J E, Yu J J, Ragueneau-Majlessi I, et al. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: A systematic review of published models, applications, and model verification [J]. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2015, 43(11): 1823-1837 |
| Li R, Barton H A, Yates P D, et al. A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41(3): 197-209 |
| Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the 'bottom up’ and 'top down’ approaches in pharmacokinetic modelling: Fitting PBPK models to observed clinical data [J]. British Journal of Clinical Pharmacology, 2015, 79(1): 48-55 |
| Xie R L, Wang X D, Xu Y P, et al. In vitro to in vivo extrapolation for predicting human equivalent dose of phenolic endocrine disrupting chemicals: PBTK model development, biological pathways, outcomes and performance [J]. The Science of the Total Environment, 2023, 897: 165271 |
| Barton H A, Chiu W A, Setzer R W, et al. Characterizing uncertainty and variability in physiologically based pharmacokinetic models: State of the science and needs for research and implementation [J]. Toxicological Sciences, 2007, 99(2): 395-402 |
| Loizou G, Spendiff M, Barton H A, et al. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: The first steps [J]. Regulatory Toxicology and Pharmacology, 2008, 50(3): 400-411 |
| Gueorguieva I, Aarons L, Ogungbenro K, et al. Optimal design for multivariate response pharmacokinetic models [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33(2): 97-124 |
| Cho K H, Shin S Y, Kolch W, et al. Experimental design in systems biology, based on parameter sensitivity analysis using a Monte Carlo method: A case study for the TNFα-mediated NF-κB signal transduction pathway [J]. SIMULATION, 2003, 79(12): 726-739 |
| Babich M A. Risk assessment of low-level chemical exposures from consumer products under the U.S. Consumer Product Safety Commission chronic hazard guidelines [J]. Environmental Health Perspectives, 1998, 106(Suppl.1): 387-390 |
| Sarigiannis D A, Karakitsios S, Dominguez-Romero E, et al. Physiology-based toxicokinetic modelling in the frame of the European Human Biomonitoring Initiative [J]. Environmental Research, 2019, 172: 216-230 |
| Nguyen H Q, Stamatis S D, Kirsch L E. A novel method for assessing drug degradation product safety using physiologically-based pharmacokinetic models and stochastic risk assessment [J]. Journal of Pharmaceutical Sciences, 2015, 104(9): 3101-3119 |
| Yang X X, Doerge D R, Teeguarden J G, et al. Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A [J]. Toxicology and Applied Pharmacology, 2015, 289(3): 442-456 |
| Crowell S R, Amin S G, Anderson K A, et al. Preliminary physiologically based pharmacokinetic models for benzopyrene and dibenzochrysene in rodents [J]. Toxicology and Applied Pharmacology, 2011, 257(3): 365-376 |
| Loccisano A E, Longnecker M P, Campbell J L Jr, et al. Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages [J]. Journal of Toxicology and Environmental Health Part A, 2013, 76(1): 25-57 |
| Tonnelier A, Coecke S, Zaldívar J M. Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model [J]. Archives of Toxicology, 2012, 86(3): 393-403 |
| Kunze A, Huwyler J, Poller B, et al. In vitro -in vivo extrapolation method to predict human renal clearance of drugs [J]. Journal of Pharmaceutical Sciences, 2014, 103(3): 994-1001 |
| Wambaugh J F, Hughes M F, Ring C L, et al. Evaluating in vitro-In vivo extrapolation of toxicokinetics [J]. Toxicological Sciences, 2018, 163(1): 152-169 |
| Rotroff D M, Wetmore B A, Dix D J, et al. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening [J]. Toxicological Sciences, 2010, 117(2): 348-358 |
| Aylward L L, Hays S M. Consideration of dosimetry in evaluation of ToxCastTM data [J]. Journal of Applied Toxicology, 2011, 31(8): 741-751 |
| Abdo N, Wetmore B A, Chappell G A, et al. In vitro screening for population variability in toxicity of pesticide-containing mixtures [J]. Environment International, 2015, 85: 147-155 |
| Wambaugh J F, Wetmore B A, Ring C L, et al. Assessing toxicokinetic uncertainty and variability in risk prioritization [J]. Toxicological Sciences, 2019, 172(2): 235-251 |
| Louisse J, Bosgra S, Blaauboer B J, et al. Prediction of in vivo developmental toxicity of all-trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic modeling [J]. Archives of Toxicology, 2015, 89(7): 1135-1148 |
| Fabian E, Gomes C, Birk B, et al. In vitro -to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds [J]. Archives of Toxicology, 2019, 93(2): 401-416 |
| Davidsen A B, Mardal M, Holm N B, et al. Ketamine analogues: Comparative toxicokinetic in vitro-in vivo extrapolation and quantification of 2-fluorodeschloroketamine in forensic blood and hair samples [J]. Journal of Pharmaceutical and Biomedical Analysis, 2020, 180: 113049 |
| Sipes N S, Wambaugh J F, Pearce R, et al. An intuitive approach for predicting potential human health risk with the Tox21 10k library [J]. Environmental Science & Technology, 2017, 51(18): 10786-10796 |
| Lin Y J, Lin Z M. In vitro -in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling [J]. Journal of Hazardous Materials, 2020, 399: 122856 |
| El-Masri H, Kleinstreuer N, Hines R N, et al. Integration of life-stage physiologically based pharmacokinetic models with adverse outcome pathways and environmental exposure models to screen for environmental hazards [J]. Toxicological Sciences, 2016, 152(1): 230-243 |
| Xie R L, Xu Y P, Ma M, et al. First metabolic profiling of 4-n-nonylphenol in human liver microsomes by integrated approaches to testing and assessment: Metabolites, pathways, and biological effects [J]. Journal of Hazardous Materials, 2023, 447: 130830 |
| Valdiviezo A, Luo Y S, Chen Z W, et al. Quantitative in vitro-to-in vivo extrapolation for mixtures: A case study of Superfund Priority List pesticides [J]. Toxicological Sciences, 2021, 183(1): 60-69 |
| Leonard J A, Tan Y M, Gilbert M, et al. Estimating margin of exposure to thyroid peroxidase inhibitors using high-throughput in vitro data, high-throughput exposure modeling, and physiologically based pharmacokinetic/pharmacodynamic modeling [J]. Toxicological Sciences, 2016, 151(1): 57-70 |
| Liu Y, Jing R Y, Wen Z N, et al. Narrowing the gap between in vitro and in vivo genetic profiles by deconvoluting toxicogenomic data in silico [J]. Frontiers in Pharmacology, 2020, 10: 1489 |
| Tong S S, Sun H, Xue C F, et al. Establishment and assessment of a novel in vitro bio-PK/PD system in predicting the in vivo pharmacokinetics and pharmacodynamics of cyclophosphamide [J]. Xenobiotica, 2018, 48(4): 368-375 |
| European Commission (EC). PARCroute Roadmap1 [R]. Belgium: European Commission, 2023 |
| European Chemicals Agency (ECHA). The use of alternatives to testing on animals for the REACH Regulation [R]. Helsinki, Finland: European Chemicals Agency, 2023 |
| Strikwold M, Spenkelink B, Woutersen R A, et al. Development of a combined in vitro physiologically based kinetic (PBK) and Monte Carlo modelling approach to predict interindividual human variation in phenol-induced developmental toxicity [J]. Toxicological Sciences, 2017, 157(2): 365-376 |
| Campbell J L, Andersen M E, Clewell H J. A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry [J]. Inhalation Toxicology, 2014, 26(6): 333-344 |
| Martin S A, McLanahan E D, Bushnell P J, et al. Species extrapolation of life-stage physiologically-based pharmacokinetic (PBPK) models to investigate the developmental toxicology of ethanol using in vitro to in vivo (IVIVE) methods [J]. Toxicological Sciences, 2015, 143(2): 512-535 |
| Ring C L, Pearce R G, Setzer R W, et al. Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability [J]. Environment International, 2017, 106: 105-118 |
| Wetmore B A, Allen B, Clewell H J 3rd, et al. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing [J]. Toxicological Sciences, 2014, 142(1): 210-224 |
| Browne P, Casey W M, Dix D J. Use of High-Throughput and Computational Approaches for Endocrine Pathway Screening [M]//Garcia-Reyero N, Murphy C A. A Systems Biology Approach to Advancing Adverse Outcome Pathways for Risk Assessment. Cham: Springer International Publishing, 2018: 15-29 |
| U.S. Environmental Protection Agency (US EPA). New approach methods work plan (v2) [R]. Washington DC, USA: U.S. Environmental Protection Agency, 2021 |
| U.S. Environmental Protection Agency (US EPA). Use of new approach methodologies to derive extrapolation factors and evaluate developmental neurotoxicity for human health risk assessment [R]. Washington DC, USA: U.S. Environmental Protection Agency, 2020 |
| Durmowicz A G, Lim R, Rogers H, et al. The U.S. food and drug administration’s experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial [J]. Annals of the American Thoracic Society, 2018, 15(1): 1-2 |
| Zhang X Y, Yang Y, Grimstein M, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: An update on the 2018-2019 submissions to the US FDA’s office of clinical pharmacology [J]. Journal of Clinical Pharmacology, 2020, 60(Suppl.1): S160-S178 |
| Organization for Economic Co-operation and Development (OECD). Guidance document on good in vitro method practices (GIVIMP) [R]. Paris: OECD, 2018 |
| Organization for Economic Co-operation and Development (OECD). Test No. 319A: Determination of in vitro intrinsic clearance using cryopreserved rainbow trout hepatocytes (RT-HEP) [R]. Paris: OECD, 2018 |
| Organization for Economic Co-operation and Development (OECD). Test No. 319B: Determination of in vitro intrinsic clearance using rainbow trout liver S9 sub-cellular fraction (RT-S9) [R]. Paris: OECD, 2018 |
| 曹正颖, 姚欣雅, 赵敏娴, 等. 大鼠经胃和皮下暴露毒死蜱的毒物代谢动力学和毒效学模型构建[J]. 中国药理学与毒理学杂志, 2016, 30(1): 74-81 Cao Z Y, Yao X Y, Zhao M X, et al. A physiologically based toxicokinetics and toxicodynamics model in rats following both oral and subcutaneous exposure to chlorpyrifos [J]. Chinese Journal of Pharmacology and Toxicology, 2016, 30(1): 74-81 (in Chinese) |
| 梁颖, 丁莹, 张留圈, 等. 氰戊菊酯生理毒物代谢动力学模型的建立[J]. 生态毒理学报, 2015, 10(3): 170-176 Liang Y, Ding Y, Zhang L Q, et al. Physiologically based toxicokinetic model for fenvalerate in mice [J]. Asian Journal of Ecotoxicology, 2015, 10(3): 170-176 (in Chinese) |
| 王阳, 刘茂. 基于生理毒代动力学模型对氯乙烯暴露后人体内剂量的求解[J]. 工业卫生与职业病, 2009, 35(5): 280-284 Wang Y, Liu M. Solution of internal doses for inhaled vinyl chloride by physiologically based toxicokinetic (PBTK) model [J]. Industrial Health and Occupational Diseases, 2009, 35(5): 280-284 (in Chinese) |
| 姚欣雅, 赵敏娴, 曹正颖, 等. 结合体质量生长函数的幼年大鼠毒死蜱经口暴露PBTK/TD模型的研究[J]. 癌变·畸变·突变, 2015, 27(4): 249-259 Yao X Y, Zhao M X, Cao Z Y, et al. A physiologically based toxicokinetic/toxicodynamic model with growth function of the juvenile rat following the oral exposure to chlorpyrifos [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(4): 249-259 (in Chinese) |
| Liu H T, Gan Z Q, Qin X Y, et al. Advances in microfluidic technologies in organoid research [J]. Advanced Healthcare Materials, 2023, 1: e2302686 |